Phototherapy of psoriasis

Slides:



Advertisements
Similar presentations
Frederick C. Fehl, III MD Dept of Dermatology SCPMG San Diego
Advertisements

Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:
Raptiva™ (efalizumab) Plaque Psoriasis: The Unmet Need
Module 4 Biological Effects of Ionizing Radiation
RADIOTHERAPY ACCIDENT IN COSTA RICA - CAUSE AND PREVENTION OF RADIATION ACCIDENTS IN HOSPITALS Module XIX.
A single centre study of the efficacy of extracorporeal photopheresis in Acute Graft Versus Host Disease Lynne Watson Nottingham University Hospital NHS.
Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
Ultraviolet Therapy Jennifer L. Doherty-Restrepo, MS, ATC, LAT
LaCasce A et al. Proc ASH 2014;Abstract 293.
Pharmacology-4 PHL 425 Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:
FDA Hearing on UV Tanning Devices March 25th, 2010 Gaithersburg, MD Dr. Michael Zanolli representing The Photomedicine Society.
Dermatology Aspects of Cutaneous T-cell Lymphoma
“My migraine always comes back” Presented by: Julio Pascual Neuroscience Area, Service of Neurology, University Hospital Central de Asturias and Ineuropa,
Hypofractionated Radiation Therapy for Early Stage Breast Cancer Patrick J. Gagnon, M.D. Resident, PGY-4 Radiation Medicine, OHSU Providence Hospital Breast.
The European Network for Traumatic Stress Training & Practice
Rituximab for the Treatment of Rheumatoid Arthritis
BAD Biologic Interventions Register (BADBIR ) An update November 2010.
Alefacept (Amevive ® ) Dosing Efficacy Compliance Links Patient Profile Introduction Clinical Experience Cost of Treatment PsoriasisGuide Side-Effects,
A Red Scaly Rash Small Group Teaching Problem Based Learning Dermatology Department College of Medicine King Saud University.
Causes and Treatment of Atopic Dermatitis
Indoor Tanning Operator Compliance & Knowledge Robin L. Hornung, MD, MPH Pediatric Dermatologist, The Everett Clinic Clinical Associate Professor UW Division.
Exercise Management Cancer. Pathophysiology Cancer is not a single disease; it is a collection of hundreds of diseases that share the common feature of.
Alexandra Pyle Bsc (Hons) Registered Nurse. What is Psoriasis?  Psoriasis is a chronic inflammatory skin disorder characterised by thickened, scaly plaques.
Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.
Xeloda ® plus oxaliplatin: rationale in colorectal cancer (CRC)  Oxaliplatin is active in CRC, especially when combined with 5-FU/leucovorin (LV)  Superior.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
PSORIASIS Ben Basger Basgers Pharmacy North Bondi Pharmacy Practice, The University of Sydney.
Patient Information - Viral Hepatitis B (HBV)
Evaluating A Systemic Therapy Psoriasis 1.Efficacy 2.Safety 3.Labeling.
EXPRESS: Response Rates at Week Placebo (n=77) Infliximab 5 mg/kg (n=301) Per cent of patients Per cent of patients with.
Phototherapy in Children Kathryn Thomson. Why are Children Different? Not just small adults –height –Body Surface Area:mass ratio –psychological differences:
1 Presented by Eugene Laska, Ph.D. at the Arthritis Advisory Committee meeting 07/30/02.
C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.
1 PHOTOTHERAPY FOR PSORIASIS Marie-Claude Marguery, Dermatology Service Purpan Hospital, Toulouse.
Phototoxic Drug Induced Photosensitivity By: Sarah Croitoru.
Perspectives on Enhancing Consumer Outcomes with Topical Antifungals
Tanning. Avae Marcello.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Puva Therapy in dermatology
Display 4-1: Therapies that Disqualified Patients as Responders  Phototherapy (PUVA, UVB)  Systemic retinoids  High potency topical corticosteroids.
Acupuncture By Katie Hicks.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Pharmacology-4 PHL 425 Second Lecture By Abdelkader Ashour, Ph.D. Phone:
1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.
Photosensitising medications
Adverse Events in Phototherapy Kathryn Thomson. Phototherapy involves exposure of the skin to ultraviolet light with or without the use of a phototoxic.
South East England Phototherapy Managed Clinical Network The First Five Years Nichola Mair Project Coordinator.
Dr V Goulden Leeds Teaching Hospitals NHS Trust
Advancements in Dermatology Practice in Uganda Dr Malik Ssempereza UNITY SKIN CLINIC ACACIA MALL KISEMENTI KAMWOKYA
Photodynamic Therapy for Pre-cancerous lesions of the skin Alan Milligan Clinical Nurse Specialist for Non-Melanoma Skin Cancers.
Number of phototherapy treatments for Psoriasis and Eczema: Audit of data collected at Whipps Cross over a three year period. Jane Watts Senior Nurse Melissa.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Combination Treatments for Psoriasis: A Systematic.
Date of download: 6/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Time Course of Topical PUVA Erythema Following.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
Omadacycline in Acute Skin and Skin Structure Infections Study (OASIS) A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and.
Vitiligo.
Diagnosis and treatment algorithm for psoriasis
Louisiana State University Radiation Safety Office
Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.
Eye Protection for Phototherapy Patients
Eucrisa™ - Crisaborole
Research where it is most needed National Respiratory Strategy
treatment of psoriasis (Evidence -based Dermatology) H.Mozayyeni
Traditional parenteral antihypertensive treatment
WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in
Narrowband-UVB treatment for psoriasis is highly economical and causes significant savings in cost for topical treatments K. Boswell,1 H. Cameron,1 J.
Psoriasis & skin cancer
British Journal of Dermatology. DOI: /bjd.16473
RCT pilot study comparing localised immersion PUVA with localised narrowband ultraviolet B (NBUVB) for treatment of palmar hand eczema D. Brass1, T.
Medical Physics Update Photophysics Sub Group
Presentation transcript:

Phototherapy of psoriasis Ljubomir B Novaković FRCP Consultant Dermatologist QEH and St. John’s Institute of Dermatology, London The Southeast of England Phototherapy Network 17th Update Meeting, St. Thomas’ Hospital, 19th June 2014

Phototherapy Traditionally means the use of artificial UVB irradiation delivered by fluorescent lamps without the addition of an exogenous photosensitizer Narrowband UVB (NB–UVB, TL–01) Broadband UVB (BB–UVB) 2

Photochemotherapy with psoralens Psoralens – naturally occurring phototoxic compounds; absorb photons and go on to interact with cell function via photochemical reactions PUVA = combined use of the furocoumarin drug psoralen (P) + ultraviolet A (UVA) Wholebody (oral, bath) Local (oral, paint, bath)

Phototherapy Mechanism of action UV radiation is absorbed by endogenous chromophores – nuclear DNA Alteration of the cytokine profile Promotion of immunosuppression Cell cycle arrest – induction of apoptosis

Phototherapy – safety Dosimetry and calibration Constancy of lamp output should be checked weekly using an independent hand–held dose meter Calibration of a UV dosimeter – on an annual basis BAD Working Party report on minimum standards for phototherapy services (www.bad.org.uk)

Minimal erythema dose (MED) and minimal phototoxic dose (MPD) The MED/MPD is the dose that provokes a just perceptible erythema Establishing MED/MPD – safe practice Skin type assessment – risk of burning

Phototherapy of psoriasis Moderate to severe psoriasis Psoriasis unresponsive to topical treatment “Thick” psoriasis – PUVA or combination therapy with UVB Children – UVB phototherapy Standard course – around 30 sessions

Phototherapy of psoriasis Protocol for oral PUVA With MPD testing (preferred) 8–methoxypsoralen (MOP) or 5–MOP Frequency of treatment: twice per week Initial dose: 70% MPD Increments: 20% Maximum single dose: 15 J/cm²

Bath PUVA Bath PUVA preferred to oral PUVA: in children significant hepatic dysfunction in patients with cataracts where psoralen–drug interaction anticipated i.e. warfarin No need for eye protection after therapy Lack of systemic side effects e.g. nausea

Phototherapy of psoriasis Protocol for bath PUVA With MPD testing (preferred) 8–MOP preferred to 5–MOP and TMP (increased risk of a blistering phototoxic reaction) Frequency of treatment: twice per week Initial dose: 50% MPD Increments: 20% Maximum single dose: 8 J/cm²

Hand and foot PUVA Frequency of treatment: twice per week Maximum single dose: 15 J/cm²

Phototherapy of psoriasis Protocol for NB–UVB With MED testing (preferred) Frequency of treatment: three times per week (preferred) Initial dose: 70% of MED Increments: 20% Maximum single dose: 5 J/cm²

Psoriasis NB–UVB is superior to BB-UVB Almost 30 years of clinical experience and data from several controlled studies have demonstrated that NB–UVB is more effective for psoriasis than NB–UVB

Randomized double–blind trial of the treatment of chronic plaque psoriasis: efficacy of PUVA vs NB–UVB therapy PUVA is significantly more effective than NB–UVB, requiring significantly fewer treatments for clearance, giving significantly longer remissions, and having a similar low incidence of short–term adverse effects However, because of better long–term safety of NB–UVB than PUVA, it should be preferred as a first choice, until disease response noted, PUVA being kept in reserve for NB–UVB failures Yones SS et al. Arch Dermatol 2006; 142(7): 836–42.

Median treatment numbers for clearance with PUVA and NB–UVB PUVA is significantly more effective than NB–UVB requiring significantly fewer treatments for clearance (PUVA median = 17, NB–UVB median = 28.5, p<0.001)

PUVA and NB–UVB are both effective Efficacy of PUVA therapy vs NB–UVB in chronic plaque psoriasis: a systematic literature review PUVA and NB–UVB are both effective PUVA tends to clear psoriasis more reliably, with fewer sessions, and provides with longer lasting clearance NB–UVB is preferred as first line phototherapy option because of long–term risks of PUVA Archier E et al.. J Eur Acad Dermatol Venereol 2012; 26 (Suppl 3): 11-21.

Phototherapy of psoriasis Minimising a risk Keep cumulative doses low Do not exceed a total number of sessions over 150 for PUVA and 200–300 for NB–UVB Combination therapy e.g. retinoids Regularly update and improve protocols; audit Life–long monitoring of patients who received excessive PUVA

Combination therapy Topicals: tar, dithranol, calcipotriol, tazarotene; corticosteroids Retinoids (Re–PUVA, Re–NB UVB) Methotrexate Biologics – main concern is potentially increased risk of skin cancer

Acute side effects of phototherapy Similar to sunburn Clinical features: erythema, edema, vesiculation and necrosis Peak before 24 hours – UVB Peak at about 72–96 hours – PUVA, related to psoralen phototoxicity More likely with topical PUVA Oral 8–MOP may cause nausea/vomiting Some patients may develop PLE

Long–term side effects of phototherapy UVB is known carcinogen No significant association between NB–UVB and BCC, SCC or melanoma in 3867 patients treated with NB–UVB in Tayside, Scotland However, cautious interpretation is required – relatively few patients who had a high treatment number and because the slow evolution of skin cancers may result in a delayed incidence peak Hearn RM et al. Br J Dermatol 2008; 159: 931–5 .

Long–term side effects of PUVA Premature photoageing Risk of cataracts PUVA lentigines Increased number of actinic keratoses SCC incidence in PUVA–treated psoriasis correlates with cumulative UVA dose Slightly increased risk of melanoma (Stern RS and the PUVA Follow-Up Study, 2001); cumulative dose or number of phototoxic episodes

Phototherapy of psoriasis Conclusion Phototherapy, in its different forms has proved itself to be well–established, safe, effective and reliable in the treatment of psoriasis NB–UVB should be preferred as a first choice because of better long–term safety PUVA is more effective than NB–UVB Combination with other treatment modalities should be considered in unresponsive patients Phototherapy will remain a cornerstone in the treatment of psoriasis